Biotechnology (78) | Severance Agreements (78)
Browse by Company
-
Adamas Pharmaceuticals Inc (1)
-
Adaptimmune Therapeutics PLC (1)
-
ADURO BIOTECH, INC. (1)
-
Aeglea BioTherapeutics, Inc. (1)
-
AILERON THERAPEUTICS INC (5)
-
AKCEA THERAPEUTICS, INC. (8)
-
Aravive, Inc. (2)
-
Arbutus Biopharma Corp (1)
-
ARENA PHARMACEUTICALS INC (4)
-
ARYA Sciences Acquisition Corp II (1)
-
Biogen Inc. (2)
-
Calyxt, Inc. (1)
-
CATABASIS PHARMACEUTICALS INC (1)
-
Cyclerion Therapeutics, Inc. (1)
-
DYNAVAX TECHNOLOGIES CORP (2)
-
Eagle Pharmaceuticals, Inc. (1)
-
Editas Medicine, Inc. (1)
-
Evelo Biosciences, Inc. (1)
-
EXACT SCIENCES CORP (1)
-
FIVE PRIME THERAPEUTICS INC (3)
-
Generation Bio Co. (1)
-
GERON CORP (1)
-
Gilead Sciences (5)
-
IMMUCELL CORP (1)
-
IMMUNOGEN INC (1)
-
IOVANCE BIOTHERAPEUTICS, INC. (1)
-
IRONWOOD PHARMACEUTICALS INC (2)
-
Kindred Biosciences, Inc. (1)
-
LEXICON PHARMACEUTICALS, INC. (2)
-
MiMedx Group, Inc. (1)
-
Mirum Pharmaceuticals, Inc. (1)
-
Ophthotech Corp. (1)
-
PDL BIOPHARMA, INC. (4)
-
Protagonist Therapeutics, Inc (3)
-
Radius Health, Inc. (1)
-
RIGEL PHARMACEUTICALS INC (1)
-
SANGAMO THERAPEUTICS, INC (1)
-
Sarepta Therapeutics, Inc. (1)
-
SUNESIS PHARMACEUTICALS INC (2)
-
Tracon Pharmaceuticals, Inc. (2)
-
Turning Point Therapeutics, Inc. (4)
-
Viela Bio, Inc. (1)
-
VITAL THERAPIES INC (1)
Recent Contracts
-
Calyxt, Inc. 2021 Executive Severance Plan
(Calyxt, Inc., Filed With SEC on March 18, 2021)
-
Release and Severance Agreement
(LEXICON PHARMACEUTICALS, INC., Filed With SEC on March 12, 2021)
-
Release and Severance Agreement
(LEXICON PHARMACEUTICALS, INC., Filed With SEC on March 12, 2021)
-
Form of Executive Severance Agreement
(Radius Health, Inc., Filed With SEC on February 25, 2021)
-
Adamas Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan
(Adamas Pharmaceuticals Inc, Filed With SEC on February 23, 2021)
-
Form of Executive Severance Benefits Agreement between Sunesis Pharmaceuticals, Inc. and certain officers
(SUNESIS PHARMACEUTICALS INC, Filed With SEC on December 22, 2020)
-
Catabasis Pharmaceuticals, Inc. Amended and Restated Executive Severance Benefits Plan, effective October 7, 2020
(CATABASIS PHARMACEUTICALS INC, Filed With SEC on November 12, 2020)
-
Amended and Restated Management Continuity and Severance Agreement, dated September 22, 2020, between Michael S. Ostrach and the Company
(DYNAVAX TECHNOLOGIES CORP, Filed With SEC on November 5, 2020)
-
Severance Benefits Policy for Specified C-Suite Executives
(ARYA Sciences Acquisition Corp II, Filed With SEC on November 2, 2020)
-
Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective July 13, 2020
(Biogen Inc., Filed With SEC on October 21, 2020)
